ALB and androgen insensitivity syndrome: The dosage subgroup analysis in the present study showed that bifid triple viable preparation at ≤1.0 g/day, 1.1–2.0 g/day, and > 2.0 g/day all significantly increased the ALB levels, suggesting that all doses of bifid triple viable preparation improved the prognoses of patients with AIS.